Haemonetics Corp (NYSE:HAE)
$ 83.51 -1.75 (-2.05%) Market Cap: 4.19 Bil Enterprise Value: 5.21 Bil PE Ratio: 34.65 PB Ratio: 4.79 GF Score: 76/100

Q2 2025 Haemonetics Corp Earnings Call Transcript

Nov 07, 2024 / 01:00PM GMT
Release Date Price: $86.53 (+10.71%)
Operator

Good day. And thank you for standing by. Welcome to the second-quarter, 2025 Haemonetics Corporation earnings conference call. (Operator Instructions)

I would now like to hand the conference over to your first speaker, Olga Guyette. Please go ahead.

Olga Guyette
Haemonetics Corp - Director - Investor Relations

Good morning everyone. Thank you for joining us for Haemonetics second-quarter, fiscal year 2025 conference call and webcast. I'm joined today by Chris Simon, our CEO and James D Arecca, our CFO. This morning, we posted our second-quarter, fiscal year 2025 results to our Investor Relations website along with our fiscal year 2025 guidance.

Before we begin, just a quick reminder that all revenue growth rates discussed today are organic unless specified otherwise and exclude the impact of currency fluctuation and acquisition. Our organic revenue growth guidance for fiscal year 2025 incorporates 15 weeks of revenue from OpSens due to the acquisition closing date being in December 2023.

We'll also refer to other non-GAAP financial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot